Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 16,351	$ 19,031
Prepaid expenses	97	83
Other current assets	1,153	28
Total current assets	17,601	19,142
Property, equipment and leasehold improvements, net	227	127
Restricted cash - non-current	150	150
Operating lease right-of-use assets	844	1,229
Prepaid clinical trial expenses		1,122
Total assets	18,822	21,770
Current liabilities:
Accounts payable	617	605
Operating lease liabilities	396	361
Accrued expenses	1,455	1,646
Total current liabilities	2,468	2,612
Other liabilities	55	94
Operating lease liabilities - non-current	553	949
Total liabilities	3,076	3,655
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.00001 par value, authorized 1,000,000 and None at December 31, 2022 and December 31, 2021. No Preferred Stock issued and outstanding at December 31, 2022 and December 31, 2021 respectively.
Common stock, $0.00001 par value, authorized 250,000,000 and 2,000,000 at December 31, 2022 and December 31, 2021, respectively. 2,429,446 and 1,370,595 shares issued and outstanding including 0 and 254 shares of unvested restricted stock awards, at December 31, 2022 and December 31, 2021, respectively.	3	3
Additional paid-in capital	264,362	256,241
Accumulated deficit	(248,619)	(238,129)
Total stockholders' equity	15,746	18,115
Total liabilities and stockholders' equity	$ 18,822	$ 21,770